H.R. 5158, introduced in September 2025, amends federal drug approval rules to make it easier for generic drug manufacturers to develop affordable alternatives that work with medical devices. Currently, when a brand-name drug is designed to work with a specific device (like an insulin pen or inhaler), generic competitors face barriers in getting approval for their own versions, even if the generic drug itself is identical to the original. This bill allows the Food and Drug Administration to approve generic drugs paired with different devices if manufacturers can demonstrate the generic drug will work just as safely and effectively with the new device as the original drug did with its device. The changes let manufacturers submit comparative studies, device compatibility data, and human factors research to prove their combination product is equivalent, potentially lowering costs for patients by encouraging generic competition in the combination drug-device market.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.